The RSV therapy market is characterized by a large and growing population of people at risk of infection every year. At greatest risk are infants and the elderly. No interventions are approved for adults, contributing to the substantial unmet need for antivirals and vaccines. Several companies are developing therapeutic antivirals and prophylactic vaccines and antibodies for RSV. The anticipated launch of these agents is expected to transform the RSV space.